Wagner Macula & Retina Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03423823
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Kapil Kapoor | Wagner Macula & Retina Center

Active Ingredients

Drugs in Phase 2 Trials (3)

aflibercept (zaltrap) (1 trial)

eplerenone (inspra) (1 trial)

ranibizumab (lucentis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3